Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT-EXT infant cohort of odevixibat in Alagille syndrome
MOH_2026-04-12_015761Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odevixibat in Alagille syndrome (ALGS), sponsored by Ipsen. Started Mar 2026; status: completed.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on MOH_2026-04-12_015761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-12_015761.